T K Nordt
Overview
Explore the profile of T K Nordt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
3.
Rossol-Haseroth K, Vogel C, Reinecke F, Burkhardt H, Wieth B, Peiter A, et al.
Internist (Berl)
. 2002 Nov;
43(9):1134-47.
PMID: 12426723
No abstract available.
4.
Nordt T, Lutzi S, Ruef J, Peter K, Klar E, Kubler W, et al.
Thromb Haemost
. 2002 Jan;
86(5):1305-13.
PMID: 11816722
Human atherosclerotic lesions exhibit increased expression of plasminogen activator inhibitor type-1 (PAI-1) that has been implicated in atherogenesis. Although vascular smooth muscle cells are a predominant source of PAI-1 expression...
5.
Nordt T, Bode C, Sobel B
Diabetologia
. 2001 Oct;
44(9):1121-4.
PMID: 11596666
Aims/hypothesis: Impaired fibrinolytic system capacity secondary to increased plasminogen activator inhibitor type-1 expression has been suggested as a pathogenetic link between insulin resistance and increased cardiovascular risk in patients with...
6.
Nordt T, Lohrmann J, Bode C
Thromb Res
. 2001 Sep;
103 Suppl 1:S1-5.
PMID: 11567663
Increased expression of plasminogen activator inhibitor type 1 (PAI-1) is now considered as an independent risk factor for cardiovascular disease. Numerous biochemical factors have been found to regulate the expression...
7.
Nordt T, Bode C
Z Kardiol
. 2001 Sep;
90(8):591-5.
PMID: 11565215
Thrombolytic therapy is an established reperfusion strategy in acute myocardial infarction with proven long-term survival benefit. New thrombolytic agents including reteplase, lanoteplase, and tenecteplase have been developed to optimize thrombolytic...
8.
9.
Nordt T, Peter K, Bode C
Herz
. 2001 May;
26 Suppl 1:42-5.
PMID: 11349626
Thrombolytic therapy is an established strategy for the treatment of acute myocardial infarction. GPIIB/IIIA BLOCKERS + MODERN THROMBOLYTIC AGENTS: At present, the most attractive development for optimizing thrombolytic therapy includes...
10.
Nordt T, Bode C
Semin Thromb Hemost
. 2000 Dec;
26(5):495-501.
PMID: 11129405
In type II diabetes mellitus the activity of the endogenous fibrinolytic system is reduced secondary to increased plasma activity of the plasminogen activator inhibitor type 1 (PAI-1). Because PAI-1 is...